| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/17/2006 | US20060182711 beneficial conjugates of water-soluble polymers and moieties having erythropoietin (EPO) activity; polyethylene glycol (PEG)-EPO conjugates |
| 08/17/2006 | US20060182705 Composition for reduction and prevention of wrinkles on the skin |
| 08/17/2006 | US20060182684 non-invasive and flexible method and carrier for drug delivery across the blood-brain barrier; brain tumors, brain metastases, stroke, schizophrenia, epilepsy, Alzheimer's, Parkinson's and Huntington's disease |
| 08/17/2006 | US20060182683 Methods for reduced renal uptake of protein conjugates |
| 08/17/2006 | US20060182260 Personal communication center performance display and status alert system |
| 08/17/2006 | DE102005005972A1 Use of thiopeptolides e.g. as substrates for a disintegrin and metalloproteinase with thrombospondin protease and for preparing medicaments to treat diseases associated with damaged tissue matrix e.g. cancer, osteoarthritis and rheumatism |
| 08/17/2006 | CA2639880A1 Anti-diabetic or anti-hypertensive dietary supplement |
| 08/17/2006 | CA2600765A1 Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by insulin-like growth factor binding protein-3 (igfbp-3) |
| 08/17/2006 | CA2599112A1 Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient |
| 08/17/2006 | CA2597754A1 Methods and uses of antibodies in the purification of interferon |
| 08/17/2006 | CA2597583A1 Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same |
| 08/17/2006 | CA2597395A1 Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| 08/17/2006 | CA2597346A1 A molecule and chimeric molecules thereof |
| 08/17/2006 | CA2597335A1 Neuroprotective agents and methods of their use |
| 08/17/2006 | CA2597329A1 Compositions and methods involving mda-7 for the treatment of cancer |
| 08/17/2006 | CA2597247A1 Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent |
| 08/17/2006 | CA2597191A1 Antimicrobial hexapeptides |
| 08/17/2006 | CA2597008A1 Immunogenic molecules |
| 08/17/2006 | CA2596505A1 Methods and compositions for the treatment of gastrointestinal disorders |
| 08/17/2006 | CA2596407A1 Methods for treating parkinson's disease |
| 08/17/2006 | CA2595526A1 Colonic delivery of active agents |
| 08/17/2006 | CA2595495A1 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 08/17/2006 | CA2594434A1 Controlled release compositions based on block copolymers |
| 08/17/2006 | CA2594405A1 Biomarkers and uses thereof |
| 08/17/2006 | CA2592776A1 Methods and compositions for minimizing accrual of inhalable insulin in the lungs |
| 08/17/2006 | CA2580882A1 Antibiotic compound |
| 08/16/2006 | EP1691197A2 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha |
| 08/16/2006 | EP1690939A2 Novel G protein-coupled receptor proteins |
| 08/16/2006 | EP1690936A1 Method of enhancing hematopoiesis-supporting ability of immortalized human bone marrow stroma cell by transferring indian hedgehog gene |
| 08/16/2006 | EP1690935A2 Generation of xenogeneic antibodies |
| 08/16/2006 | EP1690934A2 Generation of xenogeneic antibodies |
| 08/16/2006 | EP1690932A1 Bone and/or joint disease-associated gene |
| 08/16/2006 | EP1690874A2 BMP-12, BMP-13 and tendon-inducing compositions thereof |
| 08/16/2006 | EP1690870A1 Marker peptide for alzheimer's disease |
| 08/16/2006 | EP1690869A1 Peptide inhibiting angiontensin converting enzyme |
| 08/16/2006 | EP1690548A2 Cell cycle progression proteins |
| 08/16/2006 | EP1690547A1 Prevention and treatment of amyloidogenic disease |
| 08/16/2006 | EP1690546A2 Transplants for myocardial scars and method and cellular preparations therefor |
| 08/16/2006 | EP1690545A2 A combination therapy for HIV infections |
| 08/16/2006 | EP1690544A2 Pharmaceutical composition containing decoy and method of using the same |
| 08/16/2006 | EP1690535A2 Therapeutic use of nitric oxide precursor |
| 08/16/2006 | EP1690094A1 Screening assay and treatment |
| 08/16/2006 | EP1689890A2 Diagnostic tests for the detection of motor neuropathy |
| 08/16/2006 | EP1689865A2 A novel mutated nerve growth factor beta gene, proteins encoded thereby, and products and methods related thereto |
| 08/16/2006 | EP1689852A2 Compositions and methods to reduce mutagenesis |
| 08/16/2006 | EP1689851A2 Modified polypeptides with therapeutic activity and methods of use |
| 08/16/2006 | EP1689850A2 Inhibition of retroviral replication through modulation of the host cell ubiquitylation |
| 08/16/2006 | EP1689776A2 Equine p-selectin glycoprotein ligand-1 and uses thereof |
| 08/16/2006 | EP1689775A1 Gag binding proteins |
| 08/16/2006 | EP1689774A1 Sperm protective polypeptides and uses thereof |
| 08/16/2006 | EP1689773A2 Insulin releasing peptides |
| 08/16/2006 | EP1689771A1 Biologically active peptides comprising isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonine (ivtntt) |
| 08/16/2006 | EP1689770A1 Depeptidized inhibitors of hepatitis c virus ns3 protease |
| 08/16/2006 | EP1689444A1 Dna delivery with gemini cationic surfactants |
| 08/16/2006 | EP1689441A1 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 08/16/2006 | EP1689439A2 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 08/16/2006 | EP1689437A1 Erythropoietin solution formulation |
| 08/16/2006 | EP1689436A1 TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR a ANTAGONISTS |
| 08/16/2006 | EP1689429A1 Biomarkers for the efficacy of somatostatin analogue treatment |
| 08/16/2006 | EP1689428A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 08/16/2006 | EP1689427A1 Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment |
| 08/16/2006 | EP1689426A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| 08/16/2006 | EP1689425A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 08/16/2006 | EP1689424A1 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof |
| 08/16/2006 | EP1689423A2 Regulation of sperm function |
| 08/16/2006 | EP1689422A1 Plant extracts for the treatment of increased bone resorption |
| 08/16/2006 | EP1689421A1 Selective neuropeptide y2 receptor agonists |
| 08/16/2006 | EP1689420A1 Use of g-csf for treating ischemia |
| 08/16/2006 | EP1689419A1 Pharmaceutical compositions including low dosages of desmopressin |
| 08/16/2006 | EP1689418A1 Use of strain of bacillus and byproducts thereof for inhibiting formation of blood vessels |
| 08/16/2006 | EP1689401A1 Method for reducing pain |
| 08/16/2006 | EP1689397A2 Amelioration of macular degeneration and other ophthalmic diseases |
| 08/16/2006 | EP1689379A2 Methods of treating cancer with hdac inhibitors |
| 08/16/2006 | EP1689378A1 Novel use of peptide compounds for treating central neuropathic pain |
| 08/16/2006 | EP1689365A1 Drug delivery vehicles and uses thereof |
| 08/16/2006 | EP1689363A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 08/16/2006 | EP1689355A1 Selective inhibitors of nuclear factor-kb activation and uses thereof |
| 08/16/2006 | EP1689354A2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| 08/16/2006 | EP1689349A1 A method of inducing melanogenesis in humans with mc1r variant alleles |
| 08/16/2006 | EP1689348A2 Oligosaccharide compositions and use thereof in the treatment of infection |
| 08/16/2006 | EP1689223A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 08/16/2006 | EP1601772A4 Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same |
| 08/16/2006 | EP1546201A4 Nucleic acid sequences encoding novel point mutations on mglur2 and mglur3. |
| 08/16/2006 | EP1543031B1 Monomeric insulin |
| 08/16/2006 | EP1509241B1 Novel uses of cephaibols |
| 08/16/2006 | EP1469827A4 Polymorphs of sodium 4- (4-chloro-2-hydroxybenzoyl)amino butanoate |
| 08/16/2006 | EP1399476B1 Use of soluble cytokeratine-1-fragments in diagnostics |
| 08/16/2006 | EP1387691B1 Blood coagulation factor xiii for treating platelet disorders |
| 08/16/2006 | EP1297013B1 Use of taci as an anti-tumor agent |
| 08/16/2006 | EP1276853B1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 08/16/2006 | EP1276471B1 Membrane delivery system |
| 08/16/2006 | EP1272225B1 Lipid-based systems for targeting diagnostic agents |
| 08/16/2006 | EP1268530B1 Hepatitis b core antigen fusion proteins |
| 08/16/2006 | EP1220908B1 Isolated peptides which bind to mhc class ii molecules, and uses thereof |
| 08/16/2006 | EP1186301B1 Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
| 08/16/2006 | EP1183020B1 (3-trihalomethylphenoxy) (4-halophenyl) for the treatment of insulin resistance and type 2 diabetes |
| 08/16/2006 | EP1165490B1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 08/16/2006 | EP1117682B1 Chi-Conotoxin Peptides as INhibitors of Neuronal Amine Transporters |
| 08/16/2006 | EP1115876B1 Receptor based antagonists and methods of making and using |
| 08/16/2006 | EP1104675B1 Iodinated proteins for preventing iodine-deficit conditions |